In vitro drug efficacy research

In vitro drug efficacy research

Categories:

In vitro pharmacological studies provide essential data for drug development, influencing the evaluation of candidate drugs. These experiments allow for rapid drug screening, the investigation of mechanisms of action (MOA), and toxicity assessment to guide subsequent research.
Jennio Biotech maintains a reliable system for in vitro pharmacology to support these objectives. Our in vitro biology services encompass extensive cell library resources, high-throughput screening, custom tool cell development, and cellular functional studies. We can provide professional technical support and solutions based on the different research needs and objectives of our customers.

Why In Vitro Drug Efficacy Evaluation Matters

In vitro pharmacology studies are the critical gateway in preclinical drug development. Before advancing to in vivo studies or clinical trials, a candidate must demonstrate meaningful biological activity. Well-designed in vitro pharmacology assays enable researchers to:

Lead Identification

Screen large chemical libraries systematically to prioritize potent candidates.

MOA Analysis

Characterize compound-target interactions and signaling pathway modulation.

Therapeutic Window

Evaluate dose-response and selectivity in disease-specific in vitro models.

Risk Reduction

Filter ineffective or off-target compounds early to reduce late-stage attrition.

Clinical Translation

Generate predictive efficacy data to guide dosing strategies and patient selection.

At Jennio Biotech, we provide an integrated system for in vitro pharmacology. By combining extensive cell resources and advanced in vitro biology services, we deliver reproducible and regulatory-relevant data. As your dedicated preclinical CRO, we support oncology, immunotherapy, infectious diseases, and genetic disorders programs.

Our Integrated In Vitro Pharmacology Platform

Jennio Biotech’s in vitro drug efficacy research platform is built on four interconnected pillars, each designed to address a specific stage of the drug discovery and evaluation workflow. Together, they provide a seamless pipeline from initial hit identification to in-depth mechanism characterization.

Service PillarCore CapabilityKey Applications
Cell BankExtensive repository of cell lines and primary cellsModel selection, drug sensitivity profiling, reproducibility
High-Throughput ScreeningAutomated, multi-parameter compound screeningLead identification, hit-to-lead optimization, selectivity assessment
Tool Cell Development & CustomizationGenetically engineered cell lines (CRISPR/Cas9, stable transfection)Target validation, reporter assays, isogenic disease modeling
Cell Functional Study PlatformMulti-parametric functional readouts (proliferation, apoptosis, migration, signaling)MOA elucidation, phenotypic characterization, biomarker discovery

Explore Our In Vitro Efficacy Services

Click on each service below to learn more about our capabilities and how we can support your specific research needs.

Cell Bank — Comprehensive Cell Resources for Drug Discovery

A robust cell model is the foundation of any credible in vitro efficacy study. Jennio Biotech maintains a well-characterized cell bank comprising hundreds of cell lines and primary cells, spanning a wide range of tissue origins, cancer types, and disease-relevant genetic backgrounds.

Our cell bank includes:

  • Human cancer cell lines — covering major solid tumors (lung, breast, colorectal, liver, gastric, pancreatic) and hematological malignancies
  • Animal cell lines — murine, rat, and other species models for cross-species translational studies
  • Asian primary tumor cell lines — patient-derived tumor cells reflecting the genetic diversity of Asian populations, a critical resource for oncology programs targeting regional markets
  • Disease-specific and target-overexpressing models — including EGFR, HER2, KRAS, BRAF, PD-1/PD-L1, and other clinically relevant variants

All cell lines undergo rigorous authentication (STR profiling) and routine mycoplasma testing to ensure data integrity and experimental reproducibility. Our team can also source, culture, and bank rare or client-specified cell models on request. Browse Our Cell Bank Catalog →

In Vitro High-Throughput Candidate Drug Screening

Identifying the right compound from thousands of candidates demands speed, precision, and scale. Jennio Biotech’s high-throughput screening (HTS) platform enables rapid, multi-parametric evaluation of compound libraries against carefully curated cell panels tailored to your therapeutic area.

Screening capabilities include:

  • Blind Box Cell Panels — discover unexpected sensitivities by screening compounds against diverse, blinded cell collections for serendipitous hit identification
  • Cancer Type-Based Panels — focused panels grouped by tumor type (e.g., lung cancer panel, GI cancer panel) for tissue-specific efficacy profiling
  • Target-Based Panels — cell panels stratified by molecular marker expression (e.g., EGFR-mutant, HER2-amplified) for precision oncology applications
  • Custom Cell Panels — personalized panels designed to match your specific drug targets, disease models, or competitive benchmarking requirements

Our screening infrastructure supports multi-dose, multi-time-point experimental designs with standardized readouts including cell viability (MTT/CCK-8), apoptosis (Annexin V/PI), colony formation, and real-time cell analysis. Data are delivered in comprehensive reports with IC50 values, selectivity indices, and statistical analysis. Explore Screening Options →

Tool Cell Development & Customization

Standard cell models often fall short when studying specific molecular targets, resistance mechanisms, or disease-associated mutations. Jennio Biotech’s tool cell development service creates customized cell lines engineered to meet your exact research specifications.

Our genetic engineering services encompass:

  • CRISPR/Cas9 gene-edited cell lines — precise knockout, knock-in, and point mutation models for functional genomics and target validation studies
  • Disease-related gene stable strain construction — stable overexpression or knockdown of disease-relevant genes to recapitulate pathological phenotypes in vitro
  • Reporter cell lines — cells engineered with luciferase, GFP, or other reporter systems driven by pathway-specific promoters for real-time monitoring of signaling activation
  • Primary cell lines from clinical tumor samples — patient-derived primary cultures that preserve the heterogeneity and drug response characteristics of original tumors, ideal for ex vivo drug sensitivity testing

Each engineered cell line undergoes comprehensive validation including genomic confirmation, functional characterization, and stability testing over multiple passages. We provide detailed documentation and quality certificates with every deliverable. Request Custom Cell Line →

Cell Functional Study Platform

Understanding how a compound affects cellular behavior is as important as knowing whether it works. Jennio Biotech’s cell functional study platform provides a comprehensive suite of assays to dissect the phenotypic and mechanistic effects of your drug candidates.

Functional assay categories include:

  • Cell proliferation assays — MTT, CCK-8, EdU incorporation, and real-time cell analysis (RTCA) for quantifying growth inhibition and cytostatic effects
  • Cell apoptosis and cell cycle analysis — flow cytometry-based Annexin V/PI staining, caspase activity assays, and PI-based cell cycle profiling
  • Cell migration and invasion assays — transwell (Boyden chamber), wound healing (scratch), and 3D invasion models for evaluating anti-metastatic potential
  • Signal pathway analysis — Western blot, phospho-protein arrays, and reporter gene assays for mapping drug-induced signaling events
  • Cell differentiation and stemness studies — for programs targeting cell fate decisions in cancer stem cells, immune cells, or regenerative medicine

Our experienced scientists work closely with you to design assay cascades that align with your program’s stage and decision criteria, ensuring that every experiment generates actionable insights for your drug development team. View Functional Assay Capabilities →

Why Partner with Jennio Biotech for In Vitro Efficacy Studies

Selecting the right CRO partner for your in vitro pharmacology program requires more than equipment—it demands deep expertise, flexible experimental design, and strong data integrity standards.

🧬 Scientific Expertise
Our PhD-level team delivers advanced in vitro biology services supporting oncology and systems biology research.
⚙️ Integrated Workflow
A fully integrated platform for in vitro pharmacology assays, from cell banking to functional screening.

🧫 Disease Models
Unique Asian tumor models enabling translational in vitro studies for region-specific drug development.
🛡️ Data Integrity
As a trusted preclinical CRO, we ensure authenticated models and regulatory-ready reproducible data.

📡 Responsive Support
Dedicated project management ensures fast communication for complex CRO research programs.

How We Work: Typical In Vitro Efficacy Study Workflow

At Jennio Biotech, we streamline in vitro pharmacology workflows to deliver actionable data:

01
Consultation & Model Selection
Define study objectives; select optimal cell models and experimental strategy.
Deliverable: Project proposal, model recommendation, timeline.

02
Assay Development & Optimization
Establish assay conditions; optimize readouts; validate controls and Z’ factor.
Deliverable: Validated assay protocol with QC metrics.

03
Compound Screening / Testing
Perform dose-response studies; execute replicate screening and hit identification.
Deliverable: IC50/EC50 values, dose-response curves, hit selection.

04
Mechanism Characterization
Conduct functional assays including apoptosis, migration, and pathway analysis.
Deliverable: Mechanism-of-action data package with analysis.

05
Data Analysis & Reporting
Compile datasets; perform statistical analysis; generate figures and final report.
Deliverable: Complete study report with interpretation.

Frequently Asked Questions

Frequently Asked Questions about our in vitro pharmacology and in vitro biology services:

What types of cell lines in your cell bank?
We maintain an extensive in vitro pharmacology resource bank featuring human cancer cell lines (covering major solid tumors and hematological malignancies), animal cell lines, and Asian patient-derived primary tumor cells. Additionally, we provide models with clinically relevant mutations (e.g., EGFR, KRAS, HER2). If your project requires unique models, we offer custom sourcing and banking to support your specific research goals.
What is the minimum compound requirement for HTS?
Our in vitro screening platform offers exceptional flexibility. While we handle large-scale HTS, we also support focused screening of smaller libraries (50–100+ compounds). We help you optimize the library size and panel format to align with your project stage and budget.
How long does it take to complete a typical in vitro efficacy study?
Timelines vary depending on project complexity. A standard single-agent dose-response study using established cell lines typically requires 2–4 weeks from assay validation to final report. Custom tool cell development (CRISPR/Cas9 editing or stable line construction) may require 6–12 weeks depending on the engineering complexity. High-throughput screening campaigns of 1,000+ compounds generally take 4–8 weeks. We provide detailed timeline estimates during the project consultation phase.
Do you provide services for non-oncology therapeutic areas?
Yes. Our in vitro biology services extend beyond oncology to include autoimmune/inflammatory diseases, antiviral research, and metabolic disorders.
Can you help design the experimental plan for our specific drug candidate?
Absolutely. Our scientific team will work closely with you to design a tailored experimental plan based on mechanism of action, indication, and development stage.
How do you ensure data security and confidentiality for client projects?
All projects operate under strict confidentiality agreements, with controlled data access and secure reporting systems.

Ready to accelerate your drug discovery program? Contact our scientific team today to discuss your in vitro efficacy research needs. We’ll respond within 24 hours with a tailored project proposal.
Email: 3691125803@qq.com | Phone/WeChat: +86 18802035152

Listen to the voice of every customer

Share details of your inquiry, and we’ll contact you shortly.​

Contact us

Room 238, Building A, Guangzheng Science and Technology Park, No. 11 Nanyunwu Road, Huangpu District, Guangzhou, Guangdong Province, China

Business Cooperation

3691125803@qq.com

Mobile phone number/WeChat ID

+86 18802035152